Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to ipilimumab prolonged survival for patients with advanced melanoma. Nivolumab ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab significantly improved RFS for advanced melanoma compared with ipilimumab after 9 years of follow-up.

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months. HealthDay News — For patients with resected ...

A double-blinded, phase 3, randomised clinical trial (CheckMate 067) comparing nivolumab + ipilimumab (n = 314) vs monotherapy with either nivolumab (n = 316) or ipilimumab (n = 315) and comparing one ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free ...

Early recurrence after adjuvant anti-PD-1/L1 therapy for melanoma portended shorter survival, and these patients benefited more from non-PD-1-targeted systemic therapies, a subgroup analysis of a ...

Subgroups of advanced melanoma patients with a poor prognosis derive a progression-free survival (PFS) benefit from the combination of nivolumab and ipilimumab, according to research presented at the ...

For patients with stage III melanoma, the median duration of distant metastasis-free survival was more than 9 years and 83.8 months with nivolumab and ipilimumab, respectively. HealthDay News — For ...

For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the New England ...